Merck & Co Inc
1MRKX
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
AI stocks winners, laggards and losers for 2025
AI stocks flew high in 2025 despite year-end volatility. Palantir and Lam look overvalued, but opportunities remain.
stocks
12 picks for an income portfolio - Q4 2025 update
Eighteen months in and passive income growth has exceeded my target.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,092.70 | 25.50 | 0.28% |
| CAC 40 | 8,368.84 | 6.75 | 0.08% |
| DAX 40 | 25,375.87 | 114.23 | 0.45% |
| Dow JONES (US) | 49,146.70 | 357.37 | -0.72% |
| FTSE 100 | 10,123.37 | 1.23 | -0.01% |
| HKSE | 26,608.48 | 376.69 | 1.44% |
| NASDAQ | 23,656.17 | 15.17 | -0.06% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,683.29 | 12.96 | -0.09% |
| S&P 500 | 6,949.95 | 16.33 | -0.23% |
| S&P/ASX 200 | 8,759.40 | 25.80 | 0.30% |
| SSE Composite Index | 4,165.29 | 44.86 | 1.09% |